You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer
|
---|---|
Published in |
Breast Cancer Research, October 2011
|
DOI | 10.1186/bcr3038 |
Pubmed ID | |
Authors |
Rachel C Jankowitz, Kristine Cooper, Mark G Erlander, Xiao-Jun Ma, Nicole C Kesty, Hongying Li, Mamatha Chivukula, Adam Brufsky |
Abstract |
Breast Cancer Index (BCI) combines two independent biomarkers, HOXB13:IL17BR (H:I) and the 5-gene molecular grade index (MGI), that assess estrogen-mediated signalling and tumor grade, respectively. BCI stratifies early-stage estrogen-receptor positive (ER+), lymph-node negative (LN-) breast cancer patients into three risk groups and provides a continuous assessment of individual risk of distant recurrence. Objectives of the current study were to validate BCI in a clinical case series and to compare the prognostic utility of BCI and Adjuvant!Online (AO). |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 2% |
Unknown | 62 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 22% |
Student > Ph. D. Student | 12 | 19% |
Other | 10 | 16% |
Student > Bachelor | 7 | 11% |
Student > Doctoral Student | 3 | 5% |
Other | 7 | 11% |
Unknown | 10 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 27 | 43% |
Biochemistry, Genetics and Molecular Biology | 7 | 11% |
Agricultural and Biological Sciences | 6 | 10% |
Nursing and Health Professions | 3 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Other | 6 | 10% |
Unknown | 12 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2011.
All research outputs
#14,277,392
of 25,373,627 outputs
Outputs from Breast Cancer Research
#1,245
of 2,052 outputs
Outputs of similar age
#91,441
of 148,926 outputs
Outputs of similar age from Breast Cancer Research
#24
of 40 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,052 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 148,926 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.